Mo Khan of Open Orphan discusses their £6.2m Influenza human challenge study contract

Episode 822,  Aug 04, 06:31 AM

Mo Khan of CEO of Open Orphan #ORPH discusses their £6.2m contract win with a US-based biotechnology company to test its antiviral candidate using the hVIVO Influenza A human challenge study model.

Mo Khan of CEO of Open Orphan #ORPH discusses their £6.2m contract win with a US-based biotechnology company to test its antiviral candidate using the hVIVO Influenza A human challenge study model.

Highlights

The human challenge study is expected to commence in H2 2022 and will be conducted at hVIVO's state-of-the-art facilities in London. The Company expects the revenue from the contract to be recognised across 2022 and 2023. 

The client has already published preliminary data to demonstrate a favourable pharmacokinetic and safety profile. This candidate exhibits a novel mechanism of action and differs from previously approved drugs. This is an ideal time in the development of this drug to conduct a challenge study.

This is the third significant influenza human challenge study contract that Open Orphan has signed in 2022, as attention switches to potential future outbreaks in this particular disease area. Influenza is a serious global health threat with an estimated 1 billion cases per year, 3-5 million severe cases and 290,000 - 650,000 deaths per year.

Read the full RNS here